Online Learning Portal
Online Learning Portal
Hybrid Classes
We provide offline, online and recorded lectures in the same amount.
Personalised Mentoring
Every aspirant is unique and the mentoring is customised according to the strengths and weaknesses of the aspirant
Topicwise Mindmaps
In every Lecture. Director Sir will provide conceptual understanding with around 800 Mindmaps.
Quality Content
We provide you the best and Comprehensive content which comes directly or indirectly in UPSC Exam.
DAILY NEWS ANALYSIS
PRINT
09 November, 2025
3 Min Read
A novel monoclonal antibody called MAM01, developed by US researchers, has shown promising results in providing strong protection against malaria in an early clinical trial.
Purpose:
MAM01 is specifically designed to prevent malaria infection by targeting a critical protein on the malaria parasite. The antibody targets the Plasmodium falciparum circumsporozoite protein (CSP), which is a key protein found on the surface of the malaria parasite’s sporozoite stage—the form that infects the human body.
Mechanism of Action:
The antibody works by blocking infection before the parasite can reach the bloodstream, preventing the parasite from infecting the liver and subsequently causing malaria.
Clinical Trial Results:
The early-stage clinical trial demonstrated that MAM01 provided dose-dependent full protection against malaria. Importantly, the antibody exhibited minimal side effects, suggesting that it could be a safe and effective alternative to current malaria prevention methods.
Administration:
MAM01 is administered via a single injection. This long-acting antibody offers immediate protection, with the potential to provide months-long protection against malaria after just one dose.
Target Population:
This treatment is especially beneficial for young children and pregnant women, two groups that are particularly vulnerable to malaria. The ability to provide prolonged protection with a single injection could dramatically reduce the burden of malaria in endemic regions.
Monoclonal antibodies (mAbs) are laboratory-made proteins designed to mimic the body's natural immune defenses. They are engineered to target specific molecules or cells related to diseases like cancer, infections, or autoimmune disorders.
The Term "Monoclonal":
The term "monoclonal" refers to the fact that these antibodies are clones of a single type of antibody, meaning they are all identical and recognize the same target molecule.
Production of Monoclonal Antibodies:
Monoclonal antibodies are produced by cloning a single B cell (a type of immune cell that produces antibodies) and allowing it to produce large quantities of the antibody. These antibodies are then purified and used for therapeutic purposes.
Specificity:
mAbs are highly specific, meaning they are designed to recognize and bind to only one target molecule with great precision. This high specificity helps minimize the risk of side effects compared to broader, less targeted treatments.
Applications:
Monoclonal antibodies have wide-ranging applications in medicine, including the treatment of:
Cancer (e.g., targeting tumor cells)
Autoimmune diseases (e.g., rheumatoid arthritis)
Infectious diseases (e.g., malaria, HIV)
The development of MAM01 could significantly change the way malaria is prevented, especially in endemic regions where access to vaccines and conventional treatments may be limited. A single dose providing long-lasting protection would not only reduce the risk of transmission but also offer an easier and more accessible way to protect vulnerable populations, such as pregnant women and children under five, who are at the highest risk of malaria-related deaths.
The development of MAM01 represents a promising advancement in malaria prevention. With its ability to provide long-term protection through a single injection, this monoclonal antibody could revolutionize malaria control, especially in vulnerable populations.
Source: THE HINDU
PRINT
08 November, 2025
4 Min Read
A novel monoclonal antibody called MAM01, developed by US researchers, has shown promising results in providing strong protection against malaria in an early clinical trial.
Purpose:
MAM01 is specifically designed to prevent malaria infection by targeting a critical protein on the malaria parasite. The antibody targets the Plasmodium falciparum circumsporozoite protein (CSP), which is a key protein found on the surface of the malaria parasite’s sporozoite stage—the form that infects the human body.
Mechanism of Action:
The antibody works by blocking infection before the parasite can reach the bloodstream, preventing the parasite from infecting the liver and subsequently causing malaria.
Clinical Trial Results:
The early-stage clinical trial demonstrated that MAM01 provided dose-dependent full protection against malaria. Importantly, the antibody exhibited minimal side effects, suggesting that it could be a safe and effective alternative to current malaria prevention methods.
Administration:
MAM01 is administered via a single injection. This long-acting antibody offers immediate protection, with the potential to provide months-long protection against malaria after just one dose.
Target Population:
This treatment is especially beneficial for young children and pregnant women, two groups that are particularly vulnerable to malaria. The ability to provide prolonged protection with a single injection could dramatically reduce the burden of malaria in endemic regions.
Monoclonal antibodies (mAbs) are laboratory-made proteins designed to mimic the body's natural immune defenses. They are engineered to target specific molecules or cells related to diseases like cancer, infections, or autoimmune disorders.
The Term "Monoclonal":
The term "monoclonal" refers to the fact that these antibodies are clones of a single type of antibody, meaning they are all identical and recognize the same target molecule.
Production of Monoclonal Antibodies:
Monoclonal antibodies are produced by cloning a single B cell (a type of immune cell that produces antibodies) and allowing it to produce large quantities of the antibody. These antibodies are then purified and used for therapeutic purposes.
Specificity:
mAbs are highly specific, meaning they are designed to recognize and bind to only one target molecule with great precision. This high specificity helps minimize the risk of side effects compared to broader, less targeted treatments.
Applications:
Monoclonal antibodies have wide-ranging applications in medicine, including the treatment of:
Cancer (e.g., targeting tumor cells)
Autoimmune diseases (e.g., rheumatoid arthritis)
Infectious diseases (e.g., malaria, HIV)
The development of MAM01 could significantly change the way malaria is prevented, especially in endemic regions where access to vaccines and conventional treatments may be limited. A single dose providing long-lasting protection would not only reduce the risk of transmission but also offer an easier and more accessible way to protect vulnerable populations, such as pregnant women and children under five, who are at the highest risk of malaria-related deaths.
The development of MAM01 represents a promising advancement in malaria prevention. With its ability to provide long-term protection through a single injection, this monoclonal antibody could revolutionize malaria control, especially in vulnerable populations.
Source: INDIAN EXPRESS
03 Dec, 25
On 1st November, eight Indian states—Andhra Pradesh, Chhattisgarh, Haryana, Karnataka, Kerala, Madhya Pradesh, Punjab, and Tamil Nadu—along with five Union Territories—Andaman and Nicobar Islands, Chandigarh, Delhi, Lakshadweep, and Puducherry—celebrate their Formation Day. This date marks an important milestone in India
02 Dec, 25
The Turtle Wildlife Sanctuary, also known as the Kachhua Sanctuary, is located in the Varanasi district of Uttar Pradesh. It is recognised as India’s first freshwater turtle wildlife sanctuary, established to conserve endangered turtle species and support the ecological health of the Ganga River. Location and Extent The sanctuary co
02 Dec, 25
The Ministry of Education plans to introduce Artificial Intelligence (AI) and Computational Thinking (CT) from Class 3 onwards in the 2026–27 academic year. This initiative is part of the National Curriculum Framework for School Education (NCF-SE) 2023 and aligns with the National Education Policy (NEP) 2020. The aim is to prepare student
02 Dec, 25
Scientists from the Environment Department of Himachal Pradesh University (HPU) in Shimla have recently revealed that the Sal tree (Shorea robusta) is the most effective natural air purifier for combating rising pollution levels. Their findings highlight the tree’s superior capacity to trap dust, absorb gases, and cleanse the air compared
02 Dec, 25
The President of the United States has ordered the resumption of nuclear weapon testing after a gap of 33 years, the last test being in 1992. This decision marks a significant shift in global nuclear policy and has far-reaching implications for geopolitics, the environment, and international security. Status of Global Nuclear Weapon Testing
03 Dec,2025
Our Popular Courses
Module wise Prelims Batches
Mains Batches
Test Series
24 × 7 Support :
8287714422
Whatsapp :
8010068998
Email Us: query@aspireias.com
My Notes
Geography And Environment
